Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Valeant Sells Obagi to Fund that Includes China Regenerative Medicine

publication date: Nov 10, 2017

Valeant Pharma closed its $190 million sale of California-based Obagi Medical Products to Haitong International Zhonghua Finance Acquisition Fund I, L.P. and its affiliate Obagi Cosmeceuticals, LLC. Obagi sells cosmeceuticals (skin care products that contain ingredients that have been proven to have a positive effect) through dermatologists or medical spas, although they are OTC products. One of the partners of the Haitong fund is China Regenerative Medicine International Limited, which presumably has an interest in marketing the Obagi products in China. More details....

Stock Symbols: (NYSE: VRX) (HK: 8158)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.